Evidence map›Paper›PMID 38510015›Full record

ArticleHeliyon2024

PDP type brain tumor in association with multiple endocrine neoplasia type 1.

Halldór Bjarki Einarsson, Anja Lisbeth Frederiksen, Inge Soekilde Pedersen, Marianne Schmidt Ettrup, Martin Wirenfeldt, Henning Boldt, Nina Nguyen, Marianne Skovsager Andersen, Carsten Reidies Bjarkam, Frantz Rom Poulsen

Open access · goldAbstract readCase Reports
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Halldór Bjarki EinarssonDepartment of Neurosurgery, Aalborg University Hospital, Denmark.
Anja Lisbeth FrederiksenMolecular Diagnostics, Aalborg University Hospital and Clinical Cancer Research Center, Aalborg University Hospital, Denmark.
Inge Soekilde PedersenMolecular Diagnostics, Aalborg University Hospital and Clinical Cancer Research Center, Aalborg University Hospital, Denmark.
Marianne Schmidt EttrupDepartment of Pathology, Aalborg University Hospital, Denmark.
Martin WirenfeldtDepartment of Pathology, Hospital South West Jutland, Denmark.
Henning BoldtDepartment of Pathology, Odense University Hospital, Denmark.
Nina NguyenDepartment of Neuroradiology, Odense University Hospital, Denmark.
Marianne Skovsager AndersenDepartment of Endocrinology, Odense University Hospital, Denmark.
Carsten Reidies BjarkamDepartment of Neurosurgery, Aalborg University Hospital, Denmark.
Frantz Rom PoulsenDepartment of Neurosurgery, Odense University Hospital, Denmark.
Aalborg University Hospital · DKOdense University Hospital · DKUniversity of Southern Denmark · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant syndrome caused by inactivating pathogenic variants in the tumor suppressor gene menin 1 on chromosome 11q13 (Falchetti et al., 2009). The syndrome is characterized by neoplasia in two or more endocrine glands and has a high degree of penetrance. Pathogenic germline multiple neoplasia type 1 variants primarily result in neoplasia affecting the parathyroid glands, the pancreatic islet cells, and the anterior pituitary in combination. Primary hyperparathyroidism is the most common pathological manifestation of the syndrome, followed by pancreatic neuroendocrine tumors. Important genetic confirmation has been provided showing that ependymoma should be considered as a neoplasm that can occur in patients with MEN1 (Kato et al., 1996; Cuevas-Ocampo et al., 2017). The biphasic histopathological tumor entity shown in the present case we name Pleomorphic Xanthoastocytoma grade 3 differential pathology (PDP) in association with Multiple Endocrine Neoplasia type 1. This MEN1 associated tumor subtype is an extension of the findings on MEN1 associated ependymoma, where we show that the clinical phenotype itself may potentially be triggered by a frameshift germline pathogenic variant for the MEN1 gene, in combination with cyclin-dependent kinase inhibitor 1B gene germline variant and cyclin dependent kinase inhibitor 2A somatic deletion downstream of menin.

Indexed as

Cyclin-dependent kinase inhibitorEpendymomaMultiple endocrine neoplasia type 1Pleomorphic xanthoastrocytoma

Identifiers

PMID38510015
PMCPMC10951523
OpenAlexW4392714189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.